Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 May;180(5):1768-71.
doi: 10.1016/j.ajpath.2012.03.001. Epub 2012 Mar 23.

Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature

Brent A Orr  1 , Charles G Eberhart
Affiliations
Comment

Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature

Brent A Orr et al. Am J Pathol. 2012 May.

Abstract

This Commentary highlights the article by Cooper et al, which describes the association of mesenchymal glioblastoma with necrosis and poor prognosis, suggesting key signaling nodes for targeted therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Increased necrosis in GBM promotes a mesenchymal expression signature.
See this image and copyright information in PMC

Comment on

References

    1. McLendon R., Friedman A., Bigner D., Van Meir E.G., Brat D.J., Mastrogianakis G.M. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. - PMC - PubMed
    1. Madhavan S., Zenklusen J.C., Kotliarov Y., Sahni H., Fine H.A., Buetow K. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res. 2009;7:157–167. - PMC - PubMed
    1. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. - PMC - PubMed
    1. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Cancer Genome Atlas Research Network: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. - PMC - PubMed
    1. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., Verhaak R.G., Hoadley K.A., Hayes D.N., Perou C.M., Schmidt H.K., Ding L., Wilson R.K., Van Den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L.M., Buckley J., Herman J.G., Baylin S.B., Laird P.W., Aldape K. Cancer Genome Atlas Research Network: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510–522. - PMC - PubMed

Publication types